SMMT

Summit Therapeutics PLC

SMMT, USA

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis, as well as in Phase III clinical trials for the treatment of non-small lung cancer. The company was founded in 2003 and is headquartered in Miami, Florida.

https://www.smmttx.com

Stock Price

$ 0.00

0% decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
SMMT
stock
SMMT

Returns Recap: Why SMMT stock is seen as undervalued - 2025 Support & Resistance & Daily Profit Maximizing Tips Улправда

Read more →
SMMT
stock
SMMT

Barclays Upgrades Summit Therapeutics (SMMT) Nasdaq

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

STRONG BUY

Target Price:

$32.352

Analyst Picks

Strong Buy

7

Buy

3

Hold

0

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very High

67.04

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-120.56 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-88.56 %

Low ≤ 2%

High ≥ 10%

Debt to Equity

-

Very High

0.36

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 14.85% of the total shares of Summit Therapeutics PLC

1.

Baker Bros Advisors LP

(4.5397%)

since

2025/06/30

2.

FMR Inc

(1.242%)

since

2025/06/30

3.

Vanguard Group Inc

(1.1676%)

since

2025/06/30

4.

BlackRock Inc

(0.9217%)

since

2025/06/30

5.

State Street Corp

(0.5409%)

since

2025/06/30

6.

T. Rowe Price Associates, Inc.

(0.5257%)

since

2025/06/30

7.

T. Rowe Price Health Sciences

(0.419%)

since

2025/07/31

8.

Geode Capital Management, LLC

(0.3951%)

since

2025/06/30

9.

Fidelity Growth Compy Commingled Pl S

(0.3661%)

since

2025/07/31

10.

SPDR® S&P Biotech ETF

(0.3267%)

since

2025/08/31

11.

Vanguard Total Stock Mkt Idx Inv

(0.3184%)

since

2025/07/31

12.

Pictet Asset Manangement SA

(0.2913%)

since

2025/06/30

13.

UBS Group AG

(0.2819%)

since

2025/06/30

14.

Fidelity Growth Company Fund

(0.281%)

since

2025/07/31

15.

Vanguard Small Cap Index

(0.2425%)

since

2025/07/31

16.

Fidelity Select Biotechnology

(0.2197%)

since

2025/07/31

17.

Vanguard Institutional Extnd Mkt Idx Tr

(0.2042%)

since

2025/07/31

18.

NORGES BANK

(0.1871%)

since

2025/06/30

19.

Charles Schwab Investment Management Inc

(0.1739%)

since

2025/06/30

20.

APEIRON CAPITAL Ltd

(0.1617%)

since

2025/06/30

21.

Vanguard Small Cap Value Index Inv

(0.1557%)

since

2025/07/31

22.

Aberdeen Group PLC

(0.1534%)

since

2025/06/30

23.

Polar Capital Holdings PLC

(0.1346%)

since

2025/06/30

24.

Polar Capital Biotech S Inc

(0.1346%)

since

2025/07/31

25.

Polymer Capital Management (Hk) Ltd

(0.1198%)

since

2025/06/30

26.

Fiera Capital Corporation

(0.1054%)

since

2025/06/30

27.

iShares Russell Mid-Cap Growth ETF

(0.1049%)

since

2025/08/31

28.

Fidelity Extended Market Index

(0.1028%)

since

2025/07/31

29.

abrdn Healthcare Investors

(0.1004%)

since

2025/08/31

30.

Pictet-Biotech P USD

(0.097%)

since

2025/05/31

31.

Rock Springs Capital Management LP

(0.0956%)

since

2025/06/30

32.

Schwab US Small-Cap ETFâ„¢

(0.0902%)

since

2025/08/30

33.

iShares Biotechnology ETF

(0.0893%)

since

2025/08/31

34.

Fidelity Growth Company K6

(0.089%)

since

2025/07/31

35.

Morgan Stanley - Brokerage Accounts

(0.0864%)

since

2025/06/30

36.

Fidelity Series Growth Company

(0.0802%)

since

2025/07/31

37.

Fidelity Select Health Care

(0.0767%)

since

2025/07/31

38.

Bank of America Corp

(0.0762%)

since

2025/06/30

39.

Pictet-Global Megatrend Sel I USD

(0.0754%)

since

2025/05/31

40.

Millennium Management LLC

(0.0748%)

since

2025/06/30

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

-0.1785

Latest Release

Date

2025-09-30

EPS Actual

-0.2315

EPS Estimate

-0.1032

EPS Difference

-0.1283

Surprise Percent

-124.3217%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Potential Value Candidate(3.5)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(4.3)
GARP
Not Attractive for GARP(2)
Growth
Weak Growth Prospect(0.5)
Momentum
Moderate Momentum(6)
Net Net
Not Undervalued (Net-Net)(2.5)
Quality
Low Quality Business(3)
Value
Fair Value(5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.